The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Marley Spoon business combination with 468 SPAC II
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Recepta Biopharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Recepta Biopharma on a capital raise
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Refinancing of syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Goodman Fielder Limited
Advised Goodman Fielder Limited, an Australian consumer foods manufacturer and distributor, on its equity capital raising via a rights issue
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics